Zacks Investment Research Downgrades Innovus Pharmaceuticals Inc (INNV) to Hold
Innovus Pharmaceuticals Inc (NASDAQ:INNV) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Monday.
According to Zacks, “Innovus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. It delivers non-prescription medicine and consumer care products to improve men’s and women’s health and vitality. It has a robust portfolio of sexual dysfunction treatments, cough, cold, respiratory disease treatments and pain management medication, as well as skin care products. Its male and female sexual health and vitality products include Zestra (R) to increase desire, arousal, and satisfaction in women; EjectDelay (R) for treating premature ejaculation; Sensum+ (TM) that increases penile sensitivity; Zestra Glide (R); and Vesele (R) to maximize nitric oxide beneficial effects on sexual functions and brain health. Innovus Pharmaceuticals, Inc. is based in San Diego, California. “
Innovus Pharmaceuticals (NASDAQ:INNV) opened at 0.27 on Monday. The company has a 50 day moving average price of $0.29 and a 200-day moving average price of $0.26. Innovus Pharmaceuticals has a 12 month low of $0.03 and a 12 month high of $0.66. The company’s market cap is $23.61 million.
Innovus Pharmaceuticals Company Profile
Innovus Pharmaceuticals, Inc is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innovus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.